Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 9, 2008

View Archived Issues

D-Cycloserine does not affect social withdrawal in autistic children

Recent patents impart new therapeutic agents for cancer

FDA approves Hawaii Biotech's West Nile vaccine study in healthy volunteers

Dosing begins in Japanese AEGIS registration study of Soliris for PNH

BioSante begins phase III study of LibiGel for female hypoactive sexual desire disorder

Allos initiates phase IIb study of PDX in patients with non-small cell lung cancer

Phase II clinical study of MORAb-009 for pancreatic cancer begins

Exelixis initiates phase I/II trial of XL-184 for non-small cell lung cancer

Melanin-concentrating hormone, a potential antidepressant target

New ferritin light chain gene mutant mice, useful to study neuroferritinopathy / News in Context

Phase II clinical trial of Plicera for Gaucher disease gives positive results

Positive results from phase IIa clinical trial of MAXY-G34 for neutropenia

Orexigen reports positive 48-week results from phase IIb clinical trial of Empatic for obesity

Coronado initiates phase I trial of fourth-generation doxorubicin analogue

E.U. orphan drug status granted for RdCVF for retinitis pigmentosa

Ardea's lead NNRTI for HIV to enter phase IIa proof-of-concept trial

FDA approves Cialis for once daily use in treating erectile dysfunction

Novel agents for respiratory and allergic disorders claimed in recent patents

Two Movetis compounds successfully progressing through phase II clinical trials

Novel diagnostic agents disclosed by GE Healthcare

Ocera Therapeutics receives orphan drug status for AST-120 in pouchitis

Phase I trial commences for oxazolidinone antibacterial drug, TR-701

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...